Navigation Links
NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood
Date:12/4/2009

WINSTON-SALEM, N.C., Dec. 4 /PRNewswire-USNewswire/ -- A new, $2.8 million, four-year federal grant will support researchers at the University of Pittsburgh School of Medicine and their collaborators at Wake Forest University as they study why the quality of stored transfusion blood degrades over time and how to address the problem. This "storage lesion," as scientists call it, has been associated with increased risk for cardiovascular events and organ failure, particularly among compromised patients who receive multiple units of aged blood.

There is strong evidence that red blood cells lose some of their enzyme function and have a shortened life span during the time they are banked, explained co-principle investigator Mark Gladwin, M.D., director of the Vascular Medicine Institute at the University of Pittsburgh and chief of the division of pulmonary, allergy and critical care medicine at the School of Medicine.

"When the red cells hemolyze, or break apart, during storage, they leave behind micro-particle remains and the hemoglobin they contained," Dr. Gladwin said. "We suspect that after transfusion those remains lead to destruction of nitric oxide, which in turn can cause blood vessel inflammation and narrowing, as well as blood clots."

In a paper published last month in the early, online version of Current Opinion in Hematology, he and co-principal investigator Daniel B. Kim-Shapiro, Ph.D., professor of physics, Harbert Family Distinguished Chair, and director of the Translational Science Center at Wake Forest, reviewed experiments that show even low levels of red cell micro-particles and free hemoglobin scavenge nitric oxide, severely reducing its bioavailability.

"It's possible that an agent that increases nitric oxide levels, such as sodium nitrite, could be added to banked blood or given directly to transfusion patients to compensate for the potential complications of a storage lesion," noted Dr. Kim-Shapiro.

Drs. Gladwin and Kim-Shapiro have successfully collaborated during the last 10 years to evaluate how the nitric oxide, a molecule that causes blood vessels to dilate, interacts with hemoglobin in red blood cells. Their new grant, which was awarded by the National Heart, Lung and Blood Institute of the National Institutes of Health, aims to examine the role of oxidative damage, micro-particle formation and red cell destruction--both during blood storage and after transfusion -- in lab, animal and human studies; to explore key enzymes in the nitric oxide biochemical pathway; and to develop treatments to improve the quality and function of stored blood.

The Vascular Medicine Institute was founded in 2008 with the support of the Institute for Transfusion Medicine, which has sites in Pittsburgh and Chicago, and the Hemophilia Center of Western Pennsylvania.

As one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1997 and now ranks fifth in the nation, according to preliminary data for fiscal year 2008. Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region's economy. For more information about the School of Medicine, see www.medschool.pitt.edu.

Wake Forest University is a private, collegiate university in Winston-Salem, North Carolina. Consistently ranked among the nation's top universities, Wake Forest offers students the personalized attention of a small liberal arts college with the resources, technology and co-curricular opportunities of a large university. The Reynolda Campus is home to the College of Arts and Sciences, the Graduate School of Arts and Sciences, the School of Law, the Divinity School and the Schools of Business. The Bowman Gray Campus is home to Wake Forest School of Medicine, part of Wake Forest University Baptist Medical Center.

Provided by Newswise, online resource for knowledge-based news at www.newswise.com

SOURCE Wake Forest University


'/>"/>
SOURCE Wake Forest University
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
3. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
4. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
5. Chinese SFDA Grants Immtech Fast Track Status
6. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
7. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
8. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
9. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
10. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
11. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... -- Medivir AB (Nasdaq Stockholm: MVIR) today ... of Directors that will be submitted to the 2017 ... of the company,s three largest shareholders at the end ... a seat on the Nomination Committee, and the Chairman ... Committee was as follows:  ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified healthcare company, ... 31 December 2016 compared with the previous corresponding period. A full ... here . Highlights Profit ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; ... up 11%) Profit before tax of $2.12m (Dec ...
Breaking Medicine Technology:
(Date:2/24/2017)... , ... February 24, 2017 , ... ... services, which specializes in thought leadership , media relations, social media, content ... services that will be powered through Act-On, an intuitive marketing automation platform. , ...
(Date:2/23/2017)... ... 2017 , ... On February 22, 2017 the U.S. Department ... withdraw previous guidance issued by the Obama Administration requiring schools to treat transgender ... by the Obama Administration came in response to a growing number of states ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) ... Meeting. KLS is a longtime supporter of the event. , "We are pleased ... Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
(Date:2/23/2017)... ... 2017 , ... ERT, a global data and technology company ... a leading clinical development service provider, has selected ERT’s Trial Oversight suite as ... part to an array of circumstances including the use of multiple data capture ...
Breaking Medicine News(10 mins):